Verubecestat (TFA)
Product Specifications
UNSPSC Description
Verubecestat (MK-8931) TFA is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat TFA effectively reduces Aβ40 and has the potential for Alzheimer's Disease[1][2].
Target Antigen
Beta-secretase
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/verubecestat-tfa.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=NC=C(C=C1)F)NC2=CC=C(C([C@@](C)(N=C(N3C)N)CS3(=O)=O)=C2)F.O=C(C(F)(F)F)O
Molecular Weight
523.43
References & Citations
[1]Yan R, et al. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs. Transl Neurodegener. 2016 Jul 14;5:13.|[2]Scott JD, et al. Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer'sDisease. Med Chem. 2016 Dec 8;59(23):10435-10450.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-16759A/Verubecestat-TFA-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-16759A/
Clinical Information
Phase 3
CAS Number
2095432-65-6
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
